Will Rite Aid Soar Past Walgreen and CVS in 2014?

After huge gains in 2013, does Rite Aid have an encore for return-hungry investors? Find out whether the drugstore chain can keep defying rivals CVS Caremark and Walgreen in 2014.

Jan 8, 2014 at 10:49AM

Rite Aid (NYSE:RAD) put in an amazing share-price performance in 2013, with its stock almost quadrupling during the year. Yet even with the drugstore chain making huge progress last year in establishing itself as a potential survivor in the industry, Rite Aid still must face intense competition from Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS) that has threatened to limit its growth for years.

Rite Aid's breakout year in 2013 resulted from the company finally delivering on its turnaround promise, returning to profitability and encouraging investors with its future prospects. But late in the year, Rite Aid started giving shareholders reasons for concern, as some of the favorable factors that had helped boost the drugstore chain's fortunes began to subside. Without that support, the main question investors have is whether Rite Aid can keep growing or whether a pullback is inevitable. Let's take a closer look at Rite Aid's prospects for 2014.


Stats on Rite Aid

Average stock target price


Full-year fiscal 2014 EPS estimate


Full-year fiscal 2015 EPS estimate


Full-year fiscal 2014 sales growth estimate


Full-year fiscal 2015 sales growth estimate


Forward P/E


Source: Yahoo Finance.

What's in store for Rite Aid in 2014?
Analysts don't see Rite Aid having much upside potential left after its huge run last year, with the target stock price representing just a 6% rise from current levels. That level of upside isn't drastically different from what analysts show for Walgreen and CVS Caremark, but unlike Rite Aid those two stocks pay dividends, adding to the potential total return for investors in 2014.

Rite Aid also raised some new concerns in its most recent earnings report, released just before the end of 2013. Overall revenue for the third quarter climbed almost 2%, thanks largely to a 3.5% jump in pharmacy same-store sales, although front-of-store figures fell 0.2%. Yet guidance for the full fiscal 2014 came in below expectations, with earnings expected to hit between $0.17 and $0.23 per share.

Much of the challenge for Rite Aid comes from diminishing tailwinds from favorable industry factors. In the past several years, a huge number of high-profile pharmaceuticals have come off-patent, opening the door to generic competition. That's good news for Rite Aid, because generic drugs actually provide Rite Aid with higher margins than branded pharmaceuticals. More recently, the flood of new generics has slowed somewhat, and generic manufacturers have also boosted their prices, cutting margins for Rite Aid and its peers.

In addition, Walgreen and CVS have identified Rite Aid as a continuing threat and are therefore ramping up their competitive efforts. In an attempt to bolster its own poor performance in front-end sales, Walgreen has run more promotions to sell nonprescription items in its stores, sacrificing gross margin in order to boost sales volumes. Both CVS and Walgreen have used their loyalty programs in efforts to capture more long-term customers, helping Walgreen reverse the damage from its 2012 dispute with pharmacy benefit specialist Express Scripts. Rite Aid has its own loyalty program and will fight back against competitive pressures, but changing conditions in the industry will still make that fight harder than it was in 2013.

In the end, Rite Aid is highly unlikely to duplicate 2013's huge gains this year. Whether the chain can sustain its current price level without giving back ground in 2014 depends largely on its overcoming more difficult conditions and still boosting profitability. Without convincingly producing earnings growth, Rite Aid's 2013 could turn out to be a one-hit wonder for the stock.

Get smart in 2014
Rite Aid was a good stock in 2013, but there's still a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Click here to add Rite Aid to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers